alexa
Reach Us +44-1647-403003
Understanding Therapy Resistance In Mutiple Myeloma | 5179
ISSN: 2157-7013

Journal of Cell Science & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Understanding therapy resistance in mutiple myeloma

International Conference & Exhibition on Cell Science & Stem Cell Research

Apollina Goel

ScientificTracks Abstracts: J Cell Sci Ther

DOI: 10.4172/2157-7013.S1.02

Abstract
Multiple myeloma (MM) is hematologic malignancy characterized by the accumulation of malignant plasma cells in the bone marrow. Th e disease initially responds to alkylating agents, corticosteroids, and thalidomide but eventually becomes refractory. MM is extremely susceptible to radiation treatment and targeted radiotherapy with bone-seeking radiopharmaceuticals now off er a new paradigm to target this systemic malignancy. Samarium-153-ethylene diamine tetramethylene phosphonate (153-Sm-EDTMP) demonstrates good therapeutic ratio for palliation of pain in cancer patients with osseous metastases. We have shown that the proteasome inhibitor bortezomib (BTZ) can sensitize myeloma cells to conventional radiotherapy by both intrinsic and extrinsic apoptotic pathways. BTZ acts as a radiation modifi er in MM predominantly by attenuating endogenous and radiation-induced NF-κB activity. In a mouse myeloma model, we demonstrated that the combination of BTZ with 153-Sm-EDTMP resulted in increased survival time without a corresponding increase in the myelosuppressive eff ects of 153-Sm-EDTMP. We have recently proposed a novel combination of dexamethasone (Dex) plus radiation for treatment of MM in which the combination of 153-Sm-EDTMP radiotherapy and Dex selectively enhanced killing of myeloma cells. Our ongoing studies provide evidence that increases in glutathione metabolism and manganese superoxide dismutase expression play a role in IL-6-induced resistance to Dex and radiation in myeloma cells. An increased understanding of the role of endogenous and therapy-induced oxidative stress, which results from an imbalance in the production of reactive oxygen species and cellular antioxidant defenses, may off er a biochemical rationale for designing novel ways to induce oxidative stress- mediated killing of myeloma cells by radiotherapy and/or chemotherapy
Biography
Dr. Goel completed her PhD from Punjab University in India and postdoctoral studies from University of Nebraska Medical Center and Mayo Clinic. She is currently an Assistant professor in the Department of Radiation Oncology at the University of Iowa. She has published more than 25 papers in reputed journals. Dr. Goel?s research interest is on B-cell malignancies (B-cell lymphoma and multiple myeloma). Their lab is studying mechanistic pathways that can result in selective radiosensitization of tumor cells
Relevant Topics
Top